246 related articles for article (PubMed ID: 38400052)
1. Phage Display's Prospects for Early Diagnosis of Prostate Cancer.
Petrenko VA
Viruses; 2024 Feb; 16(2):. PubMed ID: 38400052
[TBL] [Abstract][Full Text] [Related]
2. Selected landscape phage probe as selective recognition interface for sensitive total prostate-specific antigen immunosensor.
Han L; Xia H; Yin L; Petrenko VA; Liu A
Biosens Bioelectron; 2018 May; 106():1-6. PubMed ID: 29414074
[TBL] [Abstract][Full Text] [Related]
3. Specific probe selection from landscape phage display library and its application in enzyme-linked immunosorbent assay of free prostate-specific antigen.
Lang Q; Wang F; Yin L; Liu M; Petrenko VA; Liu A
Anal Chem; 2014 Mar; 86(5):2767-74. PubMed ID: 24533565
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
Bantis A; Grammaticos P
Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
7. Dually targeted bioinspired nanovesicle delays advanced prostate cancer tumour growth in vivo.
Ma G; Severic M; Barker M; Pereira S; Ruiz A; Cheung CCL; Al-Jamal WT
Acta Biomater; 2021 Oct; 134():559-575. PubMed ID: 34274531
[TBL] [Abstract][Full Text] [Related]
8. Amperometric biosensors for detection of the prostate cancer marker (PSA).
Sarkar P; Pal PS; Ghosh D; Setford SJ; Tothill IE
Int J Pharm; 2002 May; 238(1-2):1-9. PubMed ID: 11996805
[TBL] [Abstract][Full Text] [Related]
9. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
[TBL] [Abstract][Full Text] [Related]
10. Phage display aided improvement of a unique prostate-specific antigen (PSA) antibody unreactive with Lys(145)-Lys(146) internally cleaved forms.
Liton MF; Peltola MT; Vehniäinen M; Kuusela E; Pettersson T; Lamminmäki U; Pettersson K; Brockmann EC
J Immunol Methods; 2015 Jul; 422():72-9. PubMed ID: 25889751
[TBL] [Abstract][Full Text] [Related]
11. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
12. Sudden PSA rise to ≥20 ng/ml and prostate cancer diagnosis in the United States: A population-based study.
Vilson FL; Li S; Brooks JD; Eisenberg ML
Prostate; 2020 Dec; 80(16):1438-1443. PubMed ID: 32956488
[TBL] [Abstract][Full Text] [Related]
13. Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist.
Hofer C; Sauerstein P; Wolter C; Scholz M; Hartung R; Breul J
Urol Int; 2000; 64(1):18-23. PubMed ID: 10782027
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.
Bunting PS; Chong N; Holowaty EJ; Goel V
Clin Biochem; 1998 Aug; 31(6):501-11. PubMed ID: 9740973
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
Lieberman R
Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
[TBL] [Abstract][Full Text] [Related]
16. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
[TBL] [Abstract][Full Text] [Related]
17. Ultrasensitive electrochemical immunosensor for PSA biomarker detection in prostate cancer cells using gold nanoparticles/PAMAM dendrimer loaded with enzyme linked aptamer as integrated triple signal amplification strategy.
Kavosi B; Salimi A; Hallaj R; Moradi F
Biosens Bioelectron; 2015 Dec; 74():915-23. PubMed ID: 26257183
[TBL] [Abstract][Full Text] [Related]
18. The prostate-specific antigen test.
Roobol MJ
Expert Opin Med Diagn; 2013 Sep; 7(5):423-6. PubMed ID: 23875974
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.
Frånlund M; Arnsrud Godtman R; Carlsson SV; Lilja H; Månsson M; Stranne J; Hugosson J
Scand J Urol; 2018 Aug; 52(4):256-262. PubMed ID: 30241447
[TBL] [Abstract][Full Text] [Related]
20. [Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"].
Imai K; Yamanaka H; Kubota Y; Miki M; Ito T; Akaza H; Uchida K; Egawa S; Kuriyama M; Watanabe H; Okihara K; Kotake T; Usami M; Arai Y; Maeda H; Sagiyama K; Saito Y; Sakai H; Shida K
Hinyokika Kiyo; 1998 Oct; 44(10):755-63. PubMed ID: 9850846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
